Aviado · Research
Longevity Daily
Tuesday, May 26, 2026
Listen
Today's Brief
Brain health takes center stage today, anchored by an updated American Heart Association scientific statement naming vascular risk control as our best tool for preserving cognitive function. The must-read: a large cohort study linking metformin to exceptional longevity in women — with decades of follow-up that no RCT could replicate. Peter Attia cuts through supplement noise with a rigorous framework for knowing whether what you take is actually working. Rounding out the issue: omega-3s earn another gold star, Singapore commits $273M to longevity research, and an audit reveals peptide therapy marketing promotes benefits nearly 4x more than risks.
10 stories2 peer-reviewed
Cognitive Health & Neuroprotection
AHA's Updated Scientific Statement: Controlling Vascular Risk Remains the Strongest Defense Against Dementia
The American Heart Association just issued its first major update since 2011 to its landmark statement on vascular contributions to cognitive impairment — and the core message is urgent: reducing blood pressure, blood sugar, and cholesterol is still the single most effective strategy to protect your brain. The update acknowledges that vascular risk alone doesn't explain all cognitive decline, and calls for research into the precise timing of interventions and circulating biomarkers that could predict who is most resilient or vulnerable. For readers monitoring their metabolic health, this is strong institutional validation that the same levers you pull for cardiovascular health are also your best brain insurance.
Read more →Brain Health Is the New Wellness Frontier — and the Hype Is Already Way Ahead of the Science
A New York Times opinion piece takes a clear-eyed look at the explosive growth in brain wellness — from David Perlmutter's Grain Brain empire to a new wave of nootropics — and delivers a necessary reality check on how little of it is supported by strong evidence. For health optimizers who already follow the research, this is a useful mirror: the space is moving fast, the consumer promises are outpacing the proof, and distinguishing signal from noise has never been harder. Worth reading as a calibration tool before your next supplement order.
Read more →Supplements & Compounds
Omega-3 Supplementation Cuts Aggression by Up to 28% — Including Both Reactive and Planned Types
A new analysis found that omega-3 supplementation reduced aggression by up to 28%, and crucially, the effect held for both reactive aggression (triggered by provocation) and proactive aggression (behavior planned in advance) — a distinction that prior research hadn't clearly established. The finding extends omega-3's résumé well beyond cardiovascular and joint health into behavioral and mental wellness. If you're already taking fish oil for inflammation or heart health, this is a meaningful additional signal with no extra cost.
Read more →Peter Attia's Framework for Deciding What Supplements and Medications Are Actually Worth Taking
In AMA #85, Peter Attia lays out a structured decision process for evaluating whether a supplement or medication is genuinely doing what you think — covering problem definition, biomarker selection, and how to design meaningful personal experiments. His core warning: "Poor problem definition almost guarantees some sort of false positive" is a precision reminder that your n-of-1 experiment needs a clear hypothesis before it starts. Essential listening for anyone managing their own stack, especially as the supplement landscape grows more complex.
Read more →Research & Papers
Common Diabetes Drug Linked to 'Exceptional Longevity' in Women — With Decades of Follow-Up Behind It
A large cohort study found that women who took metformin were significantly more likely to survive into their 90s in good health — a finding powered by an unusually long follow-up period stretching from midlife to extreme old age, a timeframe no randomized trial could realistically replicate. The researchers themselves flag the observational design as a limitation and call for RCTs to follow, but the scale and duration of the data lend it unusual credibility compared to shorter-term studies. This matters because metformin already sits near the top of many longevity physicians' off-label consideration lists; this cohort data adds meaningful weight to that conversation. If you're a woman discussing longevity strategies with your doctor, this study is worth bringing up directly.
Read more →Time-Restricted Feeding Reverses Stem Cell Aging in Fat Tissue — and Points to a Reprogramming Mechanism
In mice fed a high-fat diet, an 8-hour daily eating window over 7 months preserved the integrity and regenerative function of adipose-derived stem cells — reducing senescence markers, restoring mitochondrial health, and cutting inflammatory cytokines. The researchers found increased expression of Yamanaka reprogramming factors (Oct4, Sox2, Klf4), suggesting TRF may partially rejuvenate aged tissue through epigenetic pathways — though the study explicitly stops short of calling this causal. This is a mouse study, so direct extrapolation is premature, but it adds serious biological plausibility to the anti-aging case for time-restricted eating.
Read more →Senolytics Are Moving Into the Clinic — A Practical Primer on What's in the Pipeline
Dermatology Times offers a clinical overview of the two main classes of senescence-targeting drugs: senolytics (which selectively eliminate zombie cells by targeting their survival pathways, including p53 and p21) and senomorphics (which suppress the harmful secretions zombie cells produce). Several compounds — including navitoclax and piperlongumine — are now in clinical trials, and the piece maps which mechanisms each targets. For readers already experimenting with quercetin or dasatinib, this is a useful update on where the evidence is heading and what the pharmaceutical pipeline looks like.
Read more →Lifestyle & Nutrition
A Neurologist's Daily Playbook for Slowing Brain Atrophy — Starting in Your 30s
Brain shrinkage typically begins in the third and fourth decades of life, but a Washington Post piece featuring neurologist expertise details what current evidence supports for slowing — and in some cases partially reversing — that process. The lifestyle levers covered include specific dietary approaches, sleep optimization, and strategies for building cognitive reserve well before symptoms appear. Concrete, evidence-grounded, and actionable at any age.
Read more →Industry & Policy
Singapore Commits $273M to Longevity Research Focused on Brain Health and Physical Function
The Singapore government is deploying SGD $350 million (~US $273M) into healthy longevity research, with brain health and physical function as the twin priorities. The scale and specificity of this investment signals that government-backed research into functional aging — not just disease prevention — is becoming a serious policy priority globally. Expect a significant wave of trials, cohort studies, and translational data to emerge from this initiative over the next decade.
Read more →Peptide Therapy Websites Promote Benefits Nearly 4x More Than Safety Risks, Audit Finds
A 100-page audit of peptide therapy marketing across 25 states found that med spas, wellness clinics, and longevity practices promote potential benefits nearly four times more often than they disclose core safety information — a gap researchers are calling the "Peptide Transparency Gap." The timing matters: the FDA is actively preparing to review several popular peptide substances, and this kind of marketing imbalance tends to attract regulatory scrutiny. If you're considering peptide therapy, demand a clear safety disclosure alongside any efficacy claims.
Read more →